Asset Details
Do you wish to reserve the book?
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Do you wish to request the book?
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010
Overview
The authors report increased survival among patients with advanced hormone-refractory prostate cancer who were vaccinated against a tumor antigen. Administering three doses of autologous antigen-presenting cells stimulated by a chimeric protein comprising prostatic acid phosphatase and granulocyte–macrophage colony-stimulating factor over a 1-month period improved overall survival by 4 months, as compared with placebo.
Prostate cancer is the most common noncutaneous cancer among men in the United States and is the second leading cause of death from cancer in men.
1
Localized prostate cancer may be cured with surgery or radiation therapy, but the disease recurs in approximately 20 to 30% of patients. Androgen-deprivation therapy, the most common treatment after recurrence, is effective, but the disease eventually progresses in most patients who receive such treatment.
2
For men with metastatic castration-resistant prostate cancer, the median survival in recent phase 3 studies has ranged from 12.2 to 21.7 months.
3
–
9
A chemotherapeutic agent, docetaxel, is the only . . .
Publisher
Massachusetts Medical Society
Subject
/ Androgen Antagonists - therapeutic use
/ Antineoplastic Agents - therapeutic use
/ Biological and medical sciences
/ Cancer Vaccines - adverse effects
/ Cancer Vaccines - therapeutic use
/ Gynecology. Andrology. Obstetrics
/ Humans
/ Immunotherapy - adverse effects
/ Intercellular Adhesion Molecule-1 - adverse effects
/ Intercellular Adhesion Molecule-1 - therapeutic use
/ Male
/ Men
/ Nephrology. Urinary tract diseases
/ Prostatic Neoplasms - drug therapy
/ Prostatic Neoplasms - mortality
/ Prostatic Neoplasms - therapy
/ Tissue Extracts - adverse effects
/ Tissue Extracts - therapeutic use
/ Tumors
